Lorus Therapeutics Inc. (LOR.TO,LRUSF.PK) announced the presentation of new preclinical data for Lorus' anticancer drug, LOR-253. The data supports the treatment of lung and colon cancers with LOR-253 in combination with a variety of chemotherapy agents.
The preclinical data showed that initial treatment of non-small cell lung cancer, or NSCLC, cells with chemotherapy drugs docetaxel, paclitaxel, or cisplatin, followed by treatment with LOR-253, had significant and synergistic anticancer activity compared to either drug given alone. In animal studies, LOR-253 plus docetaxel showed significant efficacy against human NSCLC tumors when both drugs were administered at efficacious doses sequentially, compared to treatment with either agent alone at the same dose levels.
Further, the company noted that similar anticancer synergy was also seen in colon cancer cells when LOR-253 was combined with the chemotherapeutics oxaliplatin, CPT-11, or fluorouracil. In animal studies, LOR-253 plus oxaliplatin showed significant efficacy against human colon tumors when both drugs were administered sequentially, compared to either agent alone at the same dose levels.
The preclinical dose scheduling studies of LOR-253 examined the anticancer activities of LOR-253, given in combination with approved anticancer agents, at different doses and schedules.
Aiping Young, Lorus' President and CEO, said, "...The results of these studies are important because they demonstrate that LOR-253 significantly improves the antitumor activity of standard of care chemotherapy drugs used to treat NSCLC and colon cancer. These data also provide key information for designing clinical protocols for administering LOR-253 in drug combination strategies."
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org